The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. This approval follows the Phase 3 EMBER-3 trial, where the combination doubled median progression-free survival to 11.1 months compared to 5.5 months with Inluriyo alone. The all-oral regimen targets two key drivers of tumor growth with manageable side effects and no new monitoring requirements. This treatment offers a significant new option for patients with resistant ER+ breast cancer and is now available in the U.S.
Following the FDA approval of Eli Lilly's Inluriyo combined with Verzenio, Eli Lilly's stock (LLY) trades at USD 1,148.05 on Pluang as of Sep 19, 2026 01:04 WIB, showing a slight 0.35% decline in one day. The stock holds a market cap of $1.03 trillion and has a dividend yield of 0.6%, with typical investor hold time around 92 days. Current Pluang order activity leans more towards selling at 63%.
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
